Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

This study has been completed.

First Received: September 6, 2002 Last Updated: December 20, 2007 History of Changes

Sponsored by:	Amgen
Information provided by:	Amgen
ClinicalTrials.gov Identifier:	NCT00044902

Purpose

Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.

Condition	Intervention	Phase
Non-Hodgkin's Lymphoma	Drug: epratuzumab	Phase II

MedlinePlus related topics: Lymphoma

Drug Information available for: Epratuzumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL * Received and failed at least 1 prior regimen of chemotherapy * Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at least 12 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00044902

Sponsors and Collaborators

Amgen

Investigators

Study Director:

Amgen

More Information

Additional Information:

AmgenTrials clinical trials website This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Amgen Inc. ( Global Development Leader )
Study ID Numbers:	20010138
Study First Received:	September 6, 2002
Last Updated:	December 20, 2007
ClinicalTrials.gov Identifier:	NCT00044902 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Antibodies, Monoclonal
Lymphoma, Small Cleaved-cell, Diffuse
Lymphatic Diseases
Antibodies
Immunoproliferative Disorders

Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin
Lymphoma
Immunoglobulins

Additional relevant MeSH terms:

Lymphatic Diseases
Neoplasms
Immunoproliferative Disorders
Neoplasms by Histologic Type

Immune System Diseases
Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin
Lymphoma

ClinicalTrials.gov processed this record on May 07, 2009